Presentation is loading. Please wait.

Presentation is loading. Please wait.

Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy.

Published byLaurence Booth Modified over 6 years ago

Similar presentations

Presentation on theme: "Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy."— Presentation transcript:

1 Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study  Anju Bhardwaj, MD, Shafiq U. Rehman, MD, Asim A. Mohammed, MD, Hanna K. Gaggin, MD, MPH, Linda Barajas, RN, Justine Barajas, Stephanie A. Moore, MD, Dorothy Sullivan, NP, James L. Januzzi, MD  American Heart Journal  Volume 164, Issue 5, Pages e1 (November 2012) DOI: /j.ahj Copyright © 2012 Mosby, Inc. Terms and Conditions

2 Figure 1 Quality of life scores at each visit for each treatment group. At baseline, overall Minnesota Living with Heart Failure Questionnaire scores were comparable between SOC and NT-proBNP guided arms. While both groups showed improved quality of life, overall scores improved more in the NT-proBNP study arm. American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions

3 Figure 2 Correlation between relative change in Minnesota Living with Heart failure questionnaire score and relative change in NT-proBNP concentrations. A significant correlation exists after study procedures; a cubic fit line is displayed. American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions

4 Figure 3 Event rates as a function of Minnesota Living with Heart Failure Questionnaire tertile. Those with the least improvement in their quality of life scores had the highest event rates. American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions

5 Supplemental Figure 1 Improvement in quality of life compared to the change in NT-proBNP levels. The most remarkable improvement was observed in patients with most significant drop in NT-proBNP values, intermediate in patient with no change in NT-proBNP, and least in patients who had a rise in NT-proBNP levels American Heart Journal  , e1DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions

Download ppt "Quality of life and chronic heart failure therapy guided by natriuretic peptides: Results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy."

Similar presentations

Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians Michael Johnson, MD, Henry M. Feder, MD The Journal of Pediatrics Volume 157, Issue.

Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians Michael Johnson, MD, Henry M. Feder, MD The Journal of Pediatrics Volume 157, Issue.
Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.

Validity of the LaFarge equation for estimation of oxygen consumption in ventilated children with congenital heart disease younger than 3 years—A revisit.
Management of severe anemia secondary to menorrhagia in a Jehovah's Witness: a case report and treatment algorithm  Griselda Gutierrez, MD, FACOG, Joy.

Management of severe anemia secondary to menorrhagia in a Jehovah's Witness: a case report and treatment algorithm  Griselda Gutierrez, MD, FACOG, Joy.
Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation.

Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation.
Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.

Effects of β-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal.
Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST)  Kirsten E. Fleischmann,

Atrial fibrillation and quality of life after pacemaker implantation for sick sinus syndrome: Data from the Mode Selection Trial (MOST)  Kirsten E. Fleischmann,
Downstream coronary effects of drug-eluting stents

Downstream coronary effects of drug-eluting stents
Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.

Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.
Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.
Colloquium on Therapy of Right Heart Failure

Colloquium on Therapy of Right Heart Failure
Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E

Ali Ahmed, MD, MPH, Gilbert J. Perry, MD, Jerome L. Fleg, MD, Thomas E
The Epidemic of the 20th Century: Coronary Heart Disease

The Epidemic of the 20th Century: Coronary Heart Disease
Force- and relaxation-frequency relations in patients with diastolic heart failure  Takashi Yamanaka, MD, Katsuya Onishi, MD, FACC, Masaki Tanabe, MD,

Force- and relaxation-frequency relations in patients with diastolic heart failure  Takashi Yamanaka, MD, Katsuya Onishi, MD, FACC, Masaki Tanabe, MD,
The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics  Cheryl Bushnell,

The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) Registry: Design, rationale, and baseline patient characteristics  Cheryl Bushnell,
CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy.

CHronic use of Amiodarone aGAinSt Implantable cardioverter-defibrillator therapy for primary prevention of death in patients with Chagas cardiomyopathy.
Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results.

Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: One-year follow-up results.
Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.

Rationale and design of the FreezeAF trial: A randomized controlled noninferiority trial comparing isolation of the pulmonary veins with the cryoballoon.
Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,

Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population  Richard K. Cheng, MD, MS,
Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The.

Changes in mid-life fitness predicts heart failure risk at a later age independent of interval development of cardiac and noncardiac risk factors: The.
Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study.

Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study.

Similar presentations

Ads by Google